Unknown PHASE4 INTERVENTIONAL 3-arm NCT04962308

Clinical Trial of Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Healthy Adults

An Open-label,Phase Ⅳ Clinical Trial to Evaluate the Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (Vero Cell) in Healthy Population Aged From 18 to 59 Years.

Sponsor: Sinovac Research and Development Co., Ltd.

Conditions COVID-19

Interventions SARS-CoV-2 Inactivated Vaccine The SARS-CoV-2 Inactivated Vaccine

Updated 5 times since 2021 Last updated: Sep 22, 2021 Started: Jun 19, 2021 Primary completion: Aug 19, 2021 Completion: Dec 19, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04962308, this PHASE4 trial focuses on COVID-19 and remains ongoing. Sponsored by Sinovac Research and Development Co., Ltd., it has been updated 5 times since 2021, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Jul 2023 — Jul 2024 [monthly]

Unknown Status PHASE4

Status: Recruiting → Unknown Status
Oct 2021 — Jul 2023 [monthly]

Recruiting PHASE4
Sep 2021 — Oct 2021 [monthly]

Recruiting PHASE4

First recorded

Jun 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sinovac Research and Development Co., Ltd.

Data source: Sinovac Biotech Co., Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China